샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731969

세계의 보르테조밉(Bortezomib) 시장

Bortezomib
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 377 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 보르테조밉(Bortezomib) 시장은 2030년까지 2,840만 달러에 달할 전망

2024년에 2,390만 달러로 추정되는 세계의 보르테조밉 시장은 2030년에는 2,840만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 2.9%로 성장할 것으로 예측됩니다. 보르테조밉 주사는 이 리포트에서 분석한 부문의 하나이며, CAGR은 2.2%를 기록하며, 분석 기간 종료시에는 1,830만 달러에 달할 것으로 예측됩니다. 주사용 보르테조밉 분말 부문의 성장률은 분석 기간 중 CAGR 4.2%로 추정됩니다.

미국 시장은 650만 달러로 추정, 중국은 CAGR 5.4%로 성장 예측

미국의 보르테조밉 시장은 2024년에 650만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 550만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 5.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.2%와 2.2%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

세계의 보르테조밉 시장 - 주요 동향과 촉진요인 정리

보르테조밉이 혈액악성종양 치료의 핵심이 되는 이유

최초의 프로테아좀 억제제인 보르테조밉은 다발성골수종 및 맨틀세포 림프종(MCL)의 치료에서 여전히 기본 치료제로 사용되고 있습니다. 26S 프로테아좀을 선택적으로 억제하는 작용기전은 악성 형질세포의 단백질 분해 경로를 파괴하여 세포사멸과 종양 억제를 유도합니다. 그 결과, 보르테조밉은 면역조절제, 부신피질 스테로이드, 화학요법제와의 병용요법에서 1차 및 재발/불응성 치료 모두에서 중요한 역할을 하고 있습니다. 다발성골수종은 전 세계 혈액암의 대부분을 차지하고 있으며, 보르테조밉은 그 효능, 지속적 반응률, 다른 표적치료제와의 적합성이 입증되어 치료 알고리즘의 주축이 되고 있습니다.

정맥 또는 피하 주사제이기 때문에 용량에 대한 유연성이 있으며, 환자별 치료 계획을 지원할 수 있습니다. 새로운 프로테아좀 억제제 및 CAR-T 치료제의 등장에도 불구하고 보르테조밉은 특유의 안전성 프로파일, 탄탄한 임상적 근거, 국제 치료 가이드라인에서 확립된 입지를 바탕으로 모든 연령대와 병기에 걸쳐 폭넓게 처방되고 있습니다.

보르테조밉의 임상적, 상업적 타당성은 제형의 발전과 시장 확대에 따라 어떻게 유지되고 있는가?

보르테조밉의 투여 및 스케줄링이 지속적으로 최적화되면서 내약성이 개선되고 다양한 환자군에서 사용이 확대되고 있습니다. 피하투여는 정맥투여에 비해 말초신경장애 발생률을 낮추고 환자의 순응도를 향상시켜 많은 지역에서 선호되는 투약 경로가 되고 있습니다. 또한 특히 노약자나 허약 환자에서 효과와 장기적인 내약성의 균형을 맞추기 위해 용량 조절 요법이나 주 1회 투여 스케줄이 채택되고 있습니다.

제네릭 의약품의 진입과 바이오시밀러 개발로 인해, 특히 비용에 민감한 시장에서는 보르테조밉을 보다 저렴하게 이용할 수 있게 되었습니다. 일부 제조업체들은 가치 기반 가격 전략을 도입하고 더 넓은 지역에서 판매함으로써 중저소득 국가에서의 접근성을 높이고 있습니다. 이러한 접근성 확대는 골수종 발병률이 높고 종양학 자원이 부족한 지역에서 특히 큰 영향을 미치며, 보르테조밉 기반 요법이 가장 접근하기 쉽고 효과적인 치료 옵션인 경우가 많습니다.

보르테조밉 수요는 어디에서 증가하고 있으며, 어떤 환자층이 보르테조밉의 사용을 촉진하고 있는가?

북미와 유럽에서 가장 높은 수요를 보이는 보르테조밉은 1차 및 재발 요법에서 표준 치료제로 사용되고 있습니다. 미국 및 유럽에서는 보험 급여 적용과 임상적 합의에 힘입어 대학 및 지역 암 치료 기관에서 널리 사용되고 있습니다. 아시아태평양, 라틴아메리카, 아프리카 일부 지역에서는 규제 당국의 승인, 제네릭 의약품의 가용성, 암 치료 인프라의 개선으로 인해 더 넓은 시장 침투가 가능해져 수요가 증가하고 있습니다.

주요 환자군은 새로 진단된 다발성골수종 환자(특히 줄기세포 이식 부적격 환자)와 구제요법의 일환으로 프로테아좀 억제를 필요로 하는 재발/불응성 환자이며, VTD 요법(보르테조밉, 살리도마이드, 덱사메타손)이나 VRd 요법(보르테조밉, 레날리도미드, 덱사메타손)과 같은 병용요법이 널리 사용되고 있습니다. 덱사메타손)와 같은 병용요법이 널리 사용되고 있습니다. 다발성골수종 진단에서 큰 비중을 차지하는 고령자 인구는 위험에 따른 용량 조절과 관리 가능한 독성을 가진 약물이 지속적으로 판매량의 주요 견인차 역할을 하고 있습니다.

보르테조밉 시장의 세계 성장 원동력은?

보르테조밉 세계 시장은 다발성골수종 발병률의 지속적인 증가, 근거에 기반한 병용요법의 채택 확대, 비용 효율적인 제네릭 의약품의 가용성 증가에 힘입어 성장세를 보이고 있습니다. 암 치료가 정밀 요법 및 만성질환 관리 모델로 전환되고 있는 가운데, 보르테조밉의 지속적 이고 시너지 효과가 있는 약물로서의 역할은 임상적, 상업적으로 지속적인 타당성을 보장하고 있습니다. 주요 종양학 단체의 가이드라인은 치료 라인 전반에 걸쳐 보르테조밉의 사용을 지속적으로 지지하고 있으며, 혈액암 프로토콜에서 보르테조밉의 입지를 강화하고 있습니다.

경쟁 제품 제조, 유리한 비용 구조, 국제적인 자금 지원 프로그램은 특히 신흥 경제 국가에서 더 광범위한 접근을 지원하고 있습니다. 프로테아좀 억제 요법이 골수종 치료의 기본 메커니즘으로 자리 잡으면서 결정적인 의문이 제기되고 있습니다. 치료 패러다임의 진화, 생물제제와의 경쟁 심화, 장기적인 암 관리의 삶의 질 향상이라는 과제에 적응하면서도 보르테조밉이 전략적 치료 가치와 세계 접근성을 계속 유지할 수 있는가?

부문

제품 유형(주사제, 주사용 분말제), 용도(다발성골수종, 맨틀 세포 림프종, 기타 혈액 악성 종양), 최종사용자(병원, 종양 클리닉, 외래 수술 센터, 기타 최종사용자)

조사 대상 기업의 예(주목 44사)

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gland Pharma Ltd.
  • Hikma Pharmaceuticals PLC
  • Hetero Labs Ltd.
  • Johnson & Johnson
  • Meitheal Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals Inc.
  • Natco Pharma Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz International GmbH
  • Shilpa Medicare Ltd.
  • Takeda Pharmaceutical Company Ltd.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.16

Global Bortezomib Market to Reach US$28.4 Million by 2030

The global market for Bortezomib estimated at US$23.9 Million in the year 2024, is expected to reach US$28.4 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Bortezomib Injection, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$18.3 Million by the end of the analysis period. Growth in the Bortezomib Powder for Injection segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.5 Million While China is Forecast to Grow at 5.4% CAGR

The Bortezomib market in the U.S. is estimated at US$6.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Bortezomib Market - Key Trends & Drivers Summarized

Why Is Bortezomib a Cornerstone in the Treatment Landscape for Hematologic Malignancies?

Bortezomib, a first-in-class proteasome inhibitor, remains a foundational therapy in the management of multiple myeloma and mantle cell lymphoma (MCL). Its mechanism of action-selectively inhibiting the 26S proteasome-disrupts protein degradation pathways in malignant plasma cells, leading to apoptosis and tumor suppression. As a result, Bortezomib plays a critical role in both frontline and relapsed/refractory settings, often in combination regimens with immunomodulators, corticosteroids, and chemotherapeutics. With multiple myeloma accounting for a significant portion of hematologic cancers globally, Bortezomib continues to be a mainstay in treatment algorithms due to its proven efficacy, durable response rates, and compatibility with other targeted therapies.

Its injectable formulation-administered either intravenously or subcutaneously-offers dosing flexibility and supports patient-specific treatment planning. Despite the advent of newer proteasome inhibitors and CAR-T therapies, Bortezomib remains widely prescribed across age groups and disease stages due to its well-characterized safety profile, robust clinical history, and established place in international treatment guidelines.

How Are Formulation Advancements and Market Expansions Sustaining Bortezomib’s Clinical and Commercial Relevance?

Ongoing optimization of Bortezomib delivery and scheduling is enhancing tolerability and expanding its use among diverse patient populations. Subcutaneous administration has become the preferred route in many regions, offering reduced incidence of peripheral neuropathy and improved patient compliance compared to intravenous delivery. Dose-adjusted regimens and weekly schedules are also being adopted to balance efficacy with long-term tolerability, especially in elderly or frail patients.

Generic entry and biosimilar development are making Bortezomib more affordable and accessible, particularly in cost-sensitive markets. Several manufacturers are introducing value-based pricing strategies and broader geographic distribution, increasing availability in lower- and middle-income countries. This expansion is particularly impactful in regions with high myeloma burden and constrained oncology resources, where Bortezomib-based regimens often represent the most accessible and effective treatment option.

Where Is Demand for Bortezomib Growing and Which Patient Segments Are Driving Utilization?

Demand remains highest in North America and Europe, where Bortezomib is a standard-of-care component in first-line and relapse regimens. The U.S. and EU markets continue to see widespread adoption across academic and community oncology practices, supported by reimbursement coverage and strong clinical consensus. In Asia-Pacific, Latin America, and parts of Africa, demand is expanding as regulatory approvals, generic availability, and oncology infrastructure improvements enable broader market penetration.

Core patient segments include newly diagnosed multiple myeloma patients-particularly those ineligible for stem cell transplantation-as well as relapsed/refractory cases requiring proteasome inhibition as part of salvage therapy. Use in combination regimens such as VTD (Bortezomib, thalidomide, dexamethasone) or VRd (Bortezomib, lenalidomide, dexamethasone) is widespread. The elderly population, which comprises a large proportion of multiple myeloma diagnoses, continues to be a key driver of volume due to the drug’s compatibility with risk-adapted dosing and manageable toxicity.

What Is Fueling the Global Growth of the Bortezomib Market?

The global Bortezomib market is being driven by the continued rise in multiple myeloma incidence, expanding adoption of evidence-based combination therapies, and the increasing availability of cost-effective generics. As oncology treatment shifts toward precision regimens and chronic disease management models, Bortezomib's role as a durable and synergistic agent is ensuring sustained clinical and commercial relevance. Guidelines from major oncology bodies continue to support its use across lines of therapy, reinforcing its embedded status in hematologic cancer protocols.

Competitive manufacturing, favorable cost structures, and international donor programs are supporting broader access, particularly in emerging economies. As proteasome inhibition remains a cornerstone mechanism in myeloma care, a defining question emerges: Can Bortezomib continue to retain strategic therapeutic value and global accessibility-while adapting to evolving treatment paradigms, rising biologic competition, and the push for improved quality of life in long-term cancer management?

SCOPE OF STUDY:

The report analyzes the Bortezomib market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Injection, Powder for Injection); Application (Multiple Myeloma, Mantle Cell Lymphoma, Other Hematological Malignancies); End-User (Hospitals, Oncology Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gland Pharma Ltd.
  • Hikma Pharmaceuticals PLC
  • Hetero Labs Ltd.
  • Johnson & Johnson
  • Meitheal Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals Inc.
  • Natco Pharma Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz International GmbH
  • Shilpa Medicare Ltd.
  • Takeda Pharmaceutical Company Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bortezomib - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Multiple Myeloma Incidence Underpins Sustained Demand for Bortezomib Therapies
    • Inclusion in First-Line and Relapsed/Refractory Regimens Reinforces Clinical Importance of Bortezomib
    • Subcutaneous Formulations Improve Patient Tolerability and Administration Efficiency
    • Biosimilar Approvals Expand Access and Reduce Treatment Costs Across Emerging Markets
    • Combination Therapy With Immunomodulators and Steroids Enhances Overall Treatment Response
    • Real-World Evidence Supports Continued Use of Bortezomib in Elderly and High-Risk Patients
    • New Indications in Mantle Cell Lymphoma Broaden Market Beyond Multiple Myeloma
    • Manufacturer Focus on Cold Chain Stability and Ease-of-Mixing Packaging Improves Adoption
    • Resistance Management Strategies Reinforce Bortezomibs Role in Treatment Sequencing
    • Global Cancer Protocols and NCCN Guidelines Sustain Bortezomib as a Market Staple
    • Expanded Use in Maintenance Therapy and Triplet Regimens Drives Volume in Hematologic Oncology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bortezomib Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bortezomib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Powder for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Powder for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Powder for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Hematological Malignancies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oncology Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • JAPAN
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • CHINA
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • EUROPE
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Bortezomib by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • FRANCE
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • GERMANY
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Bortezomib by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • INDIA
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Bortezomib by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Bortezomib by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
  • AFRICA
    • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제